Gain Therapeutics Stock Performance
| GANX Stock | USD 1.94 0.05 2.65% |
The company retains a Market Volatility (i.e., Beta) of 0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Gain Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Gain Therapeutics is expected to be smaller as well. At this point, Gain Therapeutics has a negative expected return of -0.18%. Please make sure to check out Gain Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Gain Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Gain Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | Gain Therapeutics At A Crossroads Will GT-02287 Deliver Disease-Modifying Proof - RTTNews | 12/10/2025 |
2 | Disposition of 26424 shares by Richman Eric I of Gain Therapeutics at 3.38 subject to Rule 16b-3 | 12/11/2025 |
3 | Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease | 12/18/2025 |
4 | Gain Therapeutics Receives Buy Rating from HC Wainwright - MarketBeat | 12/19/2025 |
5 | Gain Therapeutics Upgraded to Buy Heres Why | 12/22/2025 |
6 | Gain Therapeutics, Inc. Receives Consensus Rating of Moderate Buy from Brokerages - MarketBeat | 01/02/2026 |
7 | Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week | 01/07/2026 |
8 | Disposition of 10000 shares by Nicaise Claude of Gain Therapeutics at 3.37 subject to Rule 16b-3 | 02/04/2026 |
9 | Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget | 02/18/2026 |
| Begin Period Cash Flow | 11.8 M | |
| Total Cashflows From Investing Activities | 5 M |
Gain Therapeutics Relative Risk vs. Return Landscape
If you would invest 283.00 in Gain Therapeutics on November 23, 2025 and sell it today you would lose (89.00) from holding Gain Therapeutics or give up 31.45% of portfolio value over 90 days. Gain Therapeutics is currently does not generate positive expected returns and assumes 8.8008% risk (volatility on return distribution) over the 90 days horizon. In different words, 79% of stocks are less volatile than Gain, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gain Therapeutics Target Price Odds to finish over Current Price
The tendency of Gain Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.94 | 90 days | 1.94 | about 81.87 |
Based on a normal probability distribution, the odds of Gain Therapeutics to move above the current price in 90 days from now is about 81.87 (This Gain Therapeutics probability density function shows the probability of Gain Stock to fall within a particular range of prices over 90 days) .
Gain Therapeutics Price Density |
| Price |
Predictive Modules for Gain Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Gain Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Gain Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Gain Therapeutics is not an exception. The market had few large corrections towards the Gain Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Gain Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Gain Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.11 | |
σ | Overall volatility | 0.78 | |
Ir | Information ratio | -0.03 |
Gain Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Gain Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Gain Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Gain Therapeutics generated a negative expected return over the last 90 days | |
| Gain Therapeutics has high historical volatility and very poor performance | |
| Gain Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (20.41 M) with loss before overhead, payroll, taxes, and interest of (8.95 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget |
Gain Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Gain Stock often depends not only on the future outlook of the current and potential Gain Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Gain Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.9 M | |
| Cash And Short Term Investments | 10.4 M |
Gain Therapeutics Fundamentals Growth
Gain Stock prices reflect investors' perceptions of the future prospects and financial health of Gain Therapeutics, and Gain Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gain Stock performance.
| Return On Equity | -2.62 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 61.41 M | ||||
| Shares Outstanding | 38.46 M | ||||
| Price To Book | 11.72 X | ||||
| Price To Sales | 255.50 X | ||||
| Gross Profit | (8.95 M) | ||||
| EBITDA | (20.27 M) | ||||
| Net Income | (20.41 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 653.01 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Earnings Per Share | (0.61) X | ||||
| Market Capitalization | 72.69 M | ||||
| Total Asset | 12.12 M | ||||
| Retained Earnings | (81.19 M) | ||||
| Working Capital | 7.69 M | ||||
About Gain Therapeutics Performance
Evaluating Gain Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Gain Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Gain Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.53) | (1.61) | |
| Return On Capital Employed | (2.85) | (2.71) | |
| Return On Assets | (1.52) | (1.59) | |
| Return On Equity | (3.20) | (3.04) |
Things to note about Gain Therapeutics performance evaluation
Checking the ongoing alerts about Gain Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gain Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gain Therapeutics generated a negative expected return over the last 90 days | |
| Gain Therapeutics has high historical volatility and very poor performance | |
| Gain Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (20.41 M) with loss before overhead, payroll, taxes, and interest of (8.95 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget |
- Analyzing Gain Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gain Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Gain Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gain Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gain Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gain Therapeutics' stock. These opinions can provide insight into Gain Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.